Factors in Managing Antipsychotic Therapy for Your Members With Parkinson’s Disease Psychosis
Science & Innovation Webinar
Webinar Recorded on Oct. 28, 2021
Sponsored by Acadia Pharmaceuticals Inc.
Approximately 50% of patients with Parkinson's disease (PD) may develop hallucinations and/or delusions over the course of their disease, and these non-motor symptoms may come with additional challenges, including increased healthcare utilization. The road to treatment for patients may be long and met with challenges. Dana Saffel, CEO of PharmaCare Strategies, and Babette Edgar, Area Senior Vice President of BluePeak Advisors, discuss PD psychosis and the many considerations regarding antipsychotic treatment in these patients from the payer perspective. This non-CME educational program is sponsored by Acadia Pharmaceuticals Inc.
- Dana Saffel, CEO of PharmaCare Strategies
- Babette Edgar, Area Senior Vice President of BluePeak Advisors
This webinar is sponsored, developed and presented by the sponsor. The content of this Science & Innovation Theater Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.
©2022 Acadia Pharmaceuticals Inc. Acadia is a registered trademark of Acadia Pharmaceuticals Inc. NU‐2395 1/22.